The patient's voice is important in analyzing and evaluating the effectiveness of care, as well as in assessing the value of new treatments, said Stephen Edge, MD, FACS, FASCO, vice president of Healthcare Outcomes and Policy at Roswell Park Cancer Institute.
The patient's voice is important in analyzing and evaluating the effectiveness of care, as well as in assessing the value of new treatments, said Stephen Edge, MD, FACS, FASCO, vice president of Healthcare Outcomes and Policy at Roswell Park Cancer Institute.
Transcript
How are patient reported outcomes becoming of growing importance in the transition to value-based care?
People are recognizing a couple of things—the voice of the patient is really important in analyzing and evaluating the effectiveness of care. They're also recognizing that listening to patients and giving patients the opportunity to provide information during care can actually improve their outcomes of their care meaning dealing with side effects, dealing with emotional issues, and other impacts of treatment. Dealing with those things when they're occurring rather than waiting for them to come into an office where it's intimidating to give the information that actually improves the outcome. There are data that show that measuring these and feeding the information back to providers during the course of treatment actually not only improves the effectiveness of the treatment and the quality-of-life during treatment, but it actually improves survival of patients.
What role do quality metrics play in showing what strategies efficiently improve oncology healthcare?
Measures of care can be used for a number of different things. Measures can be used to evaluate whether the care that you received is the appropriate care—that's the obvious thing; but measures can also be used to evaluate how you are doing with your treatment and to intervene so that you can improve the treatment that you're receiving and deal with side effects of the treatment you'll be giving. Organizations from ASCO to the American College of Surgeons, to all the professional organizations going up through national organizations, including the National Quality Forum, are using these measures to both evaluate the care that's being given and to help patients and their providers ensure that they're getting the best care and they're dealing with the problems associated with those care. Furthermore, these measures will help in assessing the value of care when one's doing the value assessment of a new treatment. New treatments are very expensive–there’s a lot of new treatments becoming available and the patient's voice will become important in assessing the value of these new treatments.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More